Zylacta develops novel small molecule therapeutics based on bacterial cell wall peptidoglycan. The Company currently owns two patents and is filing two new patent applications. Zylacta’s R&D activity is funded from private sources and by grants from the Maryland’s Technology Development Corporation (TEDCO) and Maryland Industrial Partnerships Program (MIPS).
The company is currently seeking to raise additional funds in a Series A round. Zylacta anticipates using this funding to perform pre-clinical and phase I clinical studies of the leading compound ZL016 by the end of 2017. The Company plans to expand its management team and add key financial, medical, drug development, and R&D officers upon completion of the Series A round.
Zylacta also plans to fund the early stage development of additional programs, and to develop and optimize new active glyco[D]peptides compounds. The company plans to outsource the pilot production of ZL016, and intends to rely on CROs for handling preclinical and clinical phases.
The company's corporate offices and R&D facility are presently located in Boyds and Gaithersburg, Maryland. Zylacta is working with Hogan & Lovell on IP issues and with Proskauer Rose on corporate development.
For more information, please email Alex Dalsky.